XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53

The XPO1 inhibitor selinexor was recently approved in relapsed/refractory DLBCL patients but only demonstrated modest anti-DLBCL efficacy, prompting us to investigate the prognostic effect of XPO1 in DLBCL patients and the rational combination therapies in high-risk DLBCL. High XPO1 expression (XPO1...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Hematol Oncol
Главные авторы: Deng, Manman, Zhang, Mingzhi, Xu-Monette, Zijun Y., Pham, Lan V., Tzankov, Alexandar, Visco, Carlo, Fang, Xiaosheng, Bhagat, Govind, Zhu, Feng, Dybkaer, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D., Choi, William W. L., Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J. M., Møller, Michael B., Parsons, Benjamin M., van Krieken, J. Han, Piris, Miguel A., Winter, Jane N., Hagemeister, Fredrick, Alinari, Lapo, Li, Yong, Andreeff, Michael, Xu, Bing, Young, Ken H.
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2020
Предметы:
Letter to the Editor
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7641823/
https://ncbi.nlm.nih.gov/pubmed/33148342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00982-3
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы